Log in

Hemostemix Stock Forecast, Price & News

0.00 (0.00 %)
(As of 10/23/2020 05:41 PM ET)
Today's Range
Now: C$0.01
50-Day Range
MA: C$0.01
52-Week Range
Now: C$0.01
Volume1.10 million shs
Average Volume906,595 shs
Market CapitalizationC$7.57 million
P/E RatioN/A
Dividend YieldN/A
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC$0.00 per share



Market CapC$7.57 million
Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 10/23/2020 05:41 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HEM News and Ratings via Email

Sign-up to receive the latest news and ratings for HEM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hemostemix (CVE:HEM) Frequently Asked Questions

How has Hemostemix's stock been impacted by Coronavirus (COVID-19)?

Hemostemix's stock was trading at C$0.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HEM shares have decreased by 33.3% and is now trading at C$0.01.
View which stocks have been most impacted by COVID-19

Who are some of Hemostemix's key competitors?

What other stocks do shareholders of Hemostemix own?

Who are Hemostemix's key executives?

Hemostemix's management team includes the following people:
  • Mr. Kyle Makofka, Chief Exec. Officer
  • Ms. Kristin Gulka CPA, CA, Chief Financial Officer
  • Ms. Eilat Bain, Director of Operations
  • Dr. Alan J. Jacobs, Chief Medical Consultant

What is Hemostemix's stock symbol?

Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."

How do I buy shares of Hemostemix?

Shares of HEM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Hemostemix's stock price today?

One share of HEM stock can currently be purchased for approximately C$0.01.

How big of a company is Hemostemix?

Hemostemix has a market capitalization of C$7.57 million.

What is Hemostemix's official website?

The official website for Hemostemix is www.hemostemix.com.

How can I contact Hemostemix?

Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207.

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.